Diagnostic Approach to Possible/Probable Celiac Disease
For adults with suspected celiac disease, start with IgA anti-tissue transglutaminase (TG2-IgA) serology while the patient is consuming gluten, and if strongly positive (>10× upper normal limit), you can now conditionally proceed without biopsy in select cases, though duodenal biopsy remains the traditional gold standard for confirmation. 1, 2
Initial Serologic Testing
The diagnostic algorithm begins with IgA TG2 antibody testing as your primary screening tool 1, 3:
- High-titre positive (>10× ULN): Virtually diagnostic when combined with positive endomysial antibody on a second sample (PPV ~100%) 1
- The 2025 ESsCD guidelines now conditionally support a no-biopsy approach for selected adults with IgA TG2 ≥10× ULN, representing a major shift from traditional practice 2
- Always check total IgA levels concurrently, as IgA deficiency occurs in ~2-3% of celiac patients and will cause false-negative IgA-based testing 1
Critical Pitfall: The Gluten Requirement
Patients MUST be consuming gluten at the time of testing - both serology and biopsy sensitivity plummet on gluten-free diets 1. If a patient has already started avoiding gluten:
- Restart normal diet with 3 slices of wheat bread daily for 1-3 months before repeat testing 1
- Some patients require even longer gluten challenge (up to several years in rare cases) 3
When to Proceed to Biopsy
Despite the new no-biopsy option, duodenal biopsy remains indicated in most scenarios 1, 2:
Biopsy is Essential When:
- TG2-IgA is positive but <10× ULN
- Clinical suspicion is high despite negative serology
- Differential diagnosis is needed (other causes of villous atrophy)
- Patient presentation is atypical or complex
Proper Biopsy Technique:
- Obtain at least 4-6 specimens from the second part of duodenum or beyond 3, 2
- Avoid relying solely on duodenal bulb biopsies (Brunner's glands and peptic changes interfere) 3
- Mucosal changes can be patchy, making multiple samples critical 3
The diagnostic histology shows: moderate-to-severe villous atrophy with crypt hyperplasia and increased intraepithelial lymphocytes 4. Isolated intraepithelial lymphocytosis without architectural changes is insufficient for diagnosis 3.
Special Testing Scenarios
IgA Deficiency (2-3% of celiac patients):
If total IgA is low, switch to:
- IgG-based testing: IgG deamidated gliadin antibody or TG2-IgG 1
- Note: IgG TG2 is NOT specific in patients with normal IgA levels 1
Seronegative but High Clinical Suspicion:
- Verify patient was consuming adequate gluten during testing
- Consider HLA-DQ2/DQ8 testing - its value lies in its negative predictive value 1, 3
- ~95% of celiac patients have DQ2, ~5% have DQ8
- Absence of both alleles effectively rules out celiac disease
- However, 40% of general population carries these alleles, so presence doesn't confirm diagnosis 3
- Proceed to biopsy if HLA-positive or clinical suspicion remains very high 3
Recognizing Atypical Presentations
Don't limit your suspicion to classic diarrhea and malabsorption 5, 6, 4. Test for celiac disease when patients present with:
Gastrointestinal:
- Chronic diarrhea, bloating, flatulence, abdominal pain
- Weight loss, poor appetite
Hematologic:
Metabolic/Endocrine:
- Unexplained hypoalbuminemia/hypoproteinemia 7
- Hypothyroidism or thyroid autoimmunity 4
- Elevated liver enzymes (hepatocellular or cholestatic pattern) 4
Musculoskeletal:
Neuropsychiatric:
Other:
High-Risk Groups Requiring Screening
Screen even asymptomatic individuals with 5:
- Type 1 diabetes
- Down syndrome
- First-degree relatives of celiac patients
- Autoimmune thyroid disease
Avoiding Common Diagnostic Errors
Never advise gluten avoidance before completing diagnostic workup - this is the most common reason for diagnostic failure 1
Don't rely on visual endoscopy alone - endoscopic appearance is not sufficiently sensitive; always biopsy 3
Don't use IgG testing in IgA-sufficient patients - it lacks specificity 1
Don't diagnose based on isolated intraepithelial lymphocytosis - requires villous architectural changes 3
Don't skip confirmatory serology if biopsy was done first - obtain celiac-specific antibodies before starting gluten-free diet 1
The strongest recent evidence from 2025 ESsCD guidelines 2 and 2019 AGA expert review 1 supports this algorithmic approach, balancing the new conditional no-biopsy pathway with the continued importance of histologic confirmation in most clinical scenarios.